Summary
Intuitive Surgical Inc. (ISRG) reported strong top-line growth in the first quarter of 2017, with total revenue increasing 13% year-over-year to $674.2 million. This growth was primarily driven by a robust increase in procedure volume, up 18%, and a corresponding 17% rise in recurring revenue, which now constitutes 77% of total revenue. While systems revenue saw a modest 4% increase, the company shipped 133 da Vinci Surgical Systems, up from 110 in the prior year quarter. The company also significantly executed a $2.0 billion accelerated share repurchase program during the quarter. Despite a reduction in reported revenue due to a customer trade-out program and litigation settlement charges, the company demonstrated solid operational performance and continued investment in research and development. The company's financial position remains strong with $3.1 billion in cash, cash equivalents, and investments as of March 31, 2017. Operating cash flow was healthy at $241.5 million, supporting the significant share repurchase activity. Management continues to emphasize investment in product development, including future generations of robotics and new catheter-based medical devices through a joint venture in China. Investors should note the ongoing litigation, particularly product liability claims, although the company currently believes these will not have a material adverse effect on its financial position.
Financial Highlights
45 data points| Revenue | $679.60M |
| Cost of Revenue | $209.80M |
| Gross Profit | $469.80M |
| R&D Expenses | $73.50M |
| SG&A Expenses | $202.90M |
| Operating Expenses | $276.40M |
| Operating Income | $193.40M |
| Net Income | $180.80M |
| EPS (Basic) | $0.54 |
| EPS (Diluted) | $0.52 |
| Shares Outstanding (Basic) | 335.70M |
| Shares Outstanding (Diluted) | 346.50M |
Key Highlights
- 1Total revenue increased by 13% to $674.2 million in Q1 2017, driven by an 18% increase in da Vinci procedures.
- 2Recurring revenue, comprising instruments, accessories, and service, grew 17% to $521.0 million, representing 77% of total revenue.
- 3Total da Vinci Surgical System shipments increased to 133 units, up from 110 in the prior year quarter.
- 4The company executed a substantial $2.0 billion accelerated share repurchase program in Q1 2017.
- 5Operating income increased 7% to $191.5 million, despite $23.4 million in deferred revenue from a customer trade-out program and $7.8 million in litigation charges.
- 6Research and development expenses increased significantly by 38% to $73.5 million, reflecting ongoing investment in new product development.
- 7The company maintains a strong liquidity position with $3.1 billion in cash, cash equivalents, and investments as of March 31, 2017.